On Friday, Zevra Therapeutics Inc (NASDAQ: ZVRA) was 5.96% up from the session before settling in for the closing price of $8.9. A 52-week range for ZVRA has been $6.19 – $13.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 29.64% over the last five years. When this article was written, the company’s average yearly earnings per share was at 152.69%. With a float of $55.47 million, this company’s outstanding shares have now reached $56.14 million.
The firm has a total of 59 workers. Let’s measure their productivity. In terms of profitability, gross margin is 71.96%, operating margin of -192.07%, and the pretax margin is 34.5%.
Zevra Therapeutics Inc (ZVRA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zevra Therapeutics Inc stocks. The insider ownership of Zevra Therapeutics Inc is 1.18%, while institutional ownership is 65.08%. The most recent insider transaction that took place on Jun 26 ’25, was worth 221,004. In this transaction Chief Legal & Compliance of this company sold 24,000 shares at a rate of $9.21, taking the stock ownership to the 42,666 shares. Before that another transaction happened on Jun 26 ’25, when Company’s Officer proposed sale 24,000 for $9.33, making the entire transaction worth $223,920.
Zevra Therapeutics Inc (ZVRA) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.69 earnings per share (EPS) during the time that was less than consensus figure (set at -0.41) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 152.69% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
You can see what Zevra Therapeutics Inc (ZVRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.05, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.55 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Analysing the last 5-days average volume posted by the [Zevra Therapeutics Inc, ZVRA], we can find that recorded value of 3.24 million was better than the volume posted last year of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 15.93%.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 46.48%, which indicates a significant increase from 22.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.61 in the past 14 days, which was higher than the 0.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.54, while its 200-day Moving Average is $8.73. Now, the first resistance to watch is $9.80. This is followed by the second major resistance level at $10.17. The third major resistance level sits at $10.66. If the price goes on to break the first support level at $8.94, it is likely to go to the next support level at $8.45. Now, if the price goes above the second support level, the third support stands at $8.08.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
There are 56,135K outstanding shares of the company, which has a market capitalization of 529.35 million. As of now, sales total 23,610 K while income totals -105,510 K. Its latest quarter income was 20,400 K while its last quarter net income were -3,100 K.
